Key result
Site-directed mutagenesis demonstrated that amino acid 94 of VP1 is a major determinant for Coxsackie B virus 5 adaptation to the murine insulinoma cell line MIN-6.
Amino acid 94 of VP1 is a critical determinant for Coxsackie B5 virus adaptation and infection of the murine insulinoma cell line MIN-6.
Does not support clinical translation; leaves open whether this determinant influences human beta-cell infection or diabetes pathogenesis.
It was shown recently that 15 successive passages of a laboratory strain of the Coxsackie B virus 5 in a mouse pancreas (CBV-5-MPP) resulted in apparent changes in the virus phenotype, which led to the capacity to induce a diabetes-like syndrome in mice. For further characterization of islet cell interactions with a passaged virus strain, a murine insulinoma cell line, MIN-6, was selected as an experimental model. The CBV-5-MPP virus strain was not able to replicate in MIN-6 cells in vitro but required adaptation over a few days for progeny production and the generation of cytopathic effects. In order to determine the genetic characteristics required for virus growth in MIN-6 cells, the whole genome of the MIN-6-adapted virus variant was sequenced, and critical amino acids were identified by comparing the sequence with that of a virus strain passaged repeatedly in the mouse pancreas. The results of site-directed mutagenesis demonstrated that only one residue, amino acid 94 of VP1, is a major determinant for virus adaptation to MIN-6 cells.
No takes yet. Share an insight, caveat, or question.
Al‐Hello et al. (2008) studied Coxsackie B virus 5 infection. Site-directed mutagenesis vs. Virus strain passaged repeatedly in the mouse pancreas was evaluated on Virus adaptation to MIN-6 cells. Site-directed mutagenesis demonstrated that amino acid 94 of VP1 is a major determinant for Coxsackie B virus 5 adaptation to the murine insulinoma cell line MIN-6.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: